AstraZeneca has entered an exclusive licence agreement with bio-platform company Alteogen, involving the latter’s ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of its cell therapy capabilities, ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk. Monday, AZ ...

Alteogen, the top corporation by market capitalization on the KOSDAQ, is experiencing a drop of over 9%. As of 2:32 p.m. on the 20th, Alteogen is trading at 381,000 won, down 38,000 won (9.07% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca has announced two separate deals that will see the company acquire EsoBiotec for up to $1 billion as well as a licensing deal with Alteogen that will expand its work in oncology and cell ...

AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the agreement ...

Amidst a backdrop of economic uncertainty and inflation concerns, global markets have experienced a downturn, with U.S. stock indexes falling due to trade policy uncertainties and growth worries. In ...